| REVIEW |
|
| Year : 2018 | Volume
: 1
| Issue : 4 | Page : 125-131 |
|
|
Engineered T Cells for glioblastoma therapy
Junjie Zhong, Jianhong Zhu
Department of Neurosurgery, Fudan University Huashan Hospital, National Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Shanghai Medical College, Fudan University, Shanghai, China
Correspondence Address:
Dr. Jianhong Zhu
Department of Neurosurgery, Fudan University Huashan Hospital, National Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Shanghai Medical College, Fudan University, No.12 Urumqi Mid Road, Shanghai 200040
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/glioma.glioma_26_18
|
|
|
Engineered T cells therapy holds promise for glioblastoma (GBM) therapy. Genetic modification of T-lymphocytes, using T cell receptors, chimeric antigen receptors, and others, is an attractive antitumor strategy, especially in large solid tumors. Recently, several clinical trials have shown an impressive tumor regression in GBM patients, demonstrating the therapeutic potential of this approach. Still, major challenges, such as antigen specificity, tumor trafficking, hostile immunosuppressive microenvironment, proliferation and persistence of T cells and unexpected adverse effects, may hinder the clinical benefit of this approach. In the present review, we summarize recent developments of engineered T cells therapy against GBM, its challenges and future.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
